The Wall Street Journal.3 hours agoThe Boss Is in the Office While Employees Hit the BeachThe Wall Street Journal. - Callum BorchersI recently pulled off something that once seemed impossible: I made an unannounced call to the boss of a major law firm on a Friday afternoon in August…and got him on his office landline. “Why are you at your desk and not on Cape Cod or a lake in Maine?” I asked when Michael Caccese, chairman of K&L …
The Wall Street Journal.7 hours agoTarget's Profit Sinks as Retailer Unloads Unwanted InventoryThe Wall Street Journal. - Sarah NassauerA glut of inventory sank profit at Target Corp. further than it expected, sparking investor concerns about the company’s response to an oversupply problem haunting retailers from Walmart Inc. to the parent of T.J. Maxx. Target’s net earnings fell 90% and operating margin declined to 1.2% in the …
The Wall Street Journal.7 hours agoAmazon Seeks Top Film Executive Amid Expansion of Entertainment ArmThe Wall Street Journal. - Erich Schwartzel, Jessica ToonkelAmazon.com Inc. is searching for a senior movie-studio executive to help lead its growing entertainment division, turning to rivals for a chance to poach an experienced Hollywood player. Amazon Studios has held conversations with several Hollywood leaders about the role, including Netflix Inc.’s …
The Wall Street Journal.7 hours agoDodge Pitches Muscle-Car Fans on EVsThe Wall Street Journal. - Ryan FeltonDodge has built a loyal following of muscle-car enthusiasts with models, such as the Challenger and Charger, whose loud, powerful engines have long been the main appeal. Now, it is betting those buyers will embrace a new kind of muscle: one that runs exclusively on battery power. On Wednesday …
The Wall Street Journal.8 hours agoOil Giants Must Face Climate-Liability Suits in States, Appeals Court RulesThe Wall Street Journal. - Erin MulvaneyA federal appeals court ruled that lawsuits by Delaware and Hoboken, N.J., seeking compensation from oil companies for the impacts of climate change should be decided in state, not federal courts. The decision Wednesday is the latest procedural victory by state and municipal governments, which have …
The Wall Street Journal.9 hours agoFDA Approves Bluebird's Gene Therapy for Rare Blood DiseaseThe Wall Street Journal. - Joseph WalkerThe Food and Drug Administration approved a gene therapy from Bluebird Bio Inc. that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient, making it one of the nation’s most expensive drugs. The FDA on Wednesday cleared the treatment, Zynteglo, for patients …
